JCN Newswires - Daiichi Sankyo Announces Completion of Phase I Trial on the Anti-influenza Drug CS-8958
DUBLIN, Ireland — Research and Markets (http://www. sibutramine. researchandmarkets.com/reports/c53518) has announced the addition of “Commercial Insight: Antibacterials - Growth in Resistance Rates Drives Niche Indications” to their offering
The global antibacterial market, valued at $25.5 billion in 2005, is highly mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing, immunosuppression and emerging resistances, especially in the hospital and former niche markets (e.g. MRSA). The community market, however, is facing a value loss following the patent expiries of several blockbusters (e.g. Pfizers Zithromax) in 2005.
Scope of this title:
Most Popular
Importance Of Strategy
Innovation that Matters: Energy & Climate
The Agile CFO: Enabling the innovation path to growth
Sales Compensation - A Guide for Sales Operations
Goal Setting Sharewares - 4 Sharewares To Help You Become Better At Goal Setting
* In-depth analysis of the current antibacterial market situation across the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK)
* Thorough assessment of underlying commercial and clinical influencers shaping the antibacterial market
* Detailed sales forecasts for key antibacterial classes, molecules and brands in each of the seven major markets
* Case study analysis of lifecycle management strategies for Zithromax (Pfizer), Rocephin (Roche) and Biaxin (Abbott) and assessment of their success
Highlights of this title:
* In 2005 the global antibacterial market was valued at approximately $25.5 billion with a modest CAGR of 5.1% since 2001. The fastest growing classes were the carbapenems, glycopeptides and “others” (e.g. Pfizers Zyvox (linezolid)). The best selling drug was J&Js/Sanofi-Aventis Levaquin (levofloxacin) with global sales of $2.4 billion.
* Although gram-positive infections such as MRSA have been a key focus over recent years, our opinion leader research revealed new concerns about gram-negative organisms such as acinetobacter, pseudomonas and ESBL producing strains.
* Ageing, immunosuppression and resistances contribute to the rising incidence of severe infections and fuel the growth of the hospital market. In contrast, the community market is facing a value loss resulting from the patent expiries of blockbusters such as Zithromax (azithromycin) and the incursion of cheap generics.
Reasons to order your copy:
* Review the clinical and commercial factors driving new product decisions in antibacterials, and the opportunities and threats facing the market
* Gain insight into future trends and lifecycle management strategies through a detailed market forecast and real case study analyses
* Understand where concerns, unmet needs and future opportunities lie by learning about the views of key antibacterial opinion leaders.
Topics Covered:
* -Market definition and overview
* -Country market assessments
* -Forecast analysis
* -Commercial impact and lifecycle management: case studies
Companies Mentioned:
* -Pfizer
* -Roche
* -Abbott
* -J&Js/Sanofi-Aventis
For more information, visit http://www.researchandmarkets.com/reports/c53518
Source: Datamonitor
COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning